Rosiglitazone attenuates allergic inflammation and inhibits expression of galectin-3 in a mouse model of allergic rhinitis.
Peroxisome proliferator activated receptor gamma (PPAR-gamma) agonists are involved in the regulation of inflammatory responses and recent studies suggest that PPAR-gamma ligands may have potential for the treatment of allergic airway disease. This study investigated the effect of the PPAR-gamma agonist, rosiglitazone, on nasal mucous allergic inflammation and galectin-3 gene expression in a murine model of allergic rhinitis (AR mice). Rosiglitazone resulted in a statistically significant attenuation of the increased numbers of inflammatory cells and Th2 cytokine levels in nasal cavity lavage fluid of AR mice. Furthermore, the expression of galectin-3 in the nasal mucosa of AR mice was statistically significantly increased. Overexpression of galectin-3 was markedly suppressed by rosiglitazone treatment. These data suggest that the PPAR-gamma agonist, rosiglitazone, may have potential in the development of therapies for allergic rhinitis.
Han
J L
JL
Department of Otolaryngology, The First Affiliated Hospital of China Medical University, Shenyang, China.
Ding
R Y
RY
Zhao
L
L
Ren
Z
Z
Jiang
X J
XJ
D000818:Animals; D004195:Disease Models, Animal; D037502:Galectin 3 / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000276:immunology; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D017817:Nasal Lavage Fluid / Q000166:cytology / Q000276:immunology; D009297:Nasal Mucosa / Q000276:immunology; D047495:PPAR gamma / Q000819:agonists*; D011897:Random Allocation; D012220:Rhinitis / Q000188:drug therapy / Q000276:immunology; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*
D037502:Galectin 3; D047495:PPAR gamma; D045162:Thiazolidinediones; D000077154:Rosiglitazone